Horizon Investments LLC Sells 1,528 Shares of Danaher Corporation $DHR

Key Points

• Horizon Investments LLC has reduced its stake in Danaher Corporation by 7.9%, selling 1,528 shares and holding 17,775 shares valued at $3,644,000 as of the last reporting period.
• Danaher Corporation reported an EPS of $1.80 for the last quarter, exceeding the consensus estimate of $1.64, with a quarterly revenue of $5.94 billion.
• Analysts have varied opinions on Danaher's stock, with price targets ranging from $240.00 to $280.00, and an average rating of "Moderate Buy".

Horizon Investments LLC lowered its position in Danaher Corporation (NYSE:DHR - Free Report) by 7.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,775 shares of the conglomerate's stock after selling 1,528 shares during the period. Horizon Investments LLC's holdings in Danaher were worth $3,644,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the company. Fox Run Management L.L.C. bought a new position in shares of Danaher in the 1st quarter worth approximately $649,000. Sei Investments Co. raised its position in shares of Danaher by 0.9% in the 1st quarter. Sei Investments Co. now owns 1,026,281 shares of the conglomerate's stock worth $233,655,000 after acquiring an additional 8,924 shares in the last quarter. Kovitz Investment Group Partners LLC raised its position in shares of Danaher by 5.3% in the 1st quarter. Kovitz Investment Group Partners LLC now owns 304,909 shares of the conglomerate's stock worth $62,507,000 after acquiring an additional 15,267 shares in the last quarter. Vestmark Advisory Solutions Inc. grew its stake in shares of Danaher by 62.3% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 13,238 shares of the conglomerate's stock worth $2,714,000 after buying an additional 5,080 shares during the last quarter. Finally, Harfst & Associates Inc. purchased a new stake in shares of Danaher in the 1st quarter worth approximately $676,000. Institutional investors own 79.05% of the company's stock.

Analyst Ratings Changes

DHR has been the topic of several recent research reports. HSBC cut their price target on Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research note on Wednesday, July 23rd. Leerink Partners upped their price target on Danaher from $225.00 to $230.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 23rd. Finally, UBS Group cut their price target on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a research note on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, Danaher presently has an average rating of "Moderate Buy" and a consensus price target of $247.61.

Danaher Stock Up 1.5%

DHR traded up $3.2250 during trading on Tuesday, hitting $212.2350. 4,850,978 shares of the company's stock traded hands, compared to its average volume of 4,241,318. The company's 50 day simple moving average is $200.14 and its two-hundred day simple moving average is $199.45. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $279.90. The stock has a market capitalization of $151.97 billion, a price-to-earnings ratio of 45.16, a PEG ratio of 2.94 and a beta of 0.73.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company's revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.